This report analyzes the worldwide markets for Anxiety Disorders in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 63 companies including many key and niche players such as AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline Plc, H. Lundbeck A/S, Mylan, Inc., Neurocrine Biosciences, Inc., Pfizer, Inc., Ratiopharm, Sanofi-Aventis, Valeant Pharmaceuticals International, and Watson Laboratories, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
- Quantitative Techniques & Analytics 3
- Product Definitions and Scope of Study 3

2. INDUSTRY OVERVIEW 5

Anxiety Disorders: A Prelude 5
Future Outlook - Market Challenged by Generics and Efficacy Issues 5
Current and Future Analysis 6
A Snapshot of the Global Market Opportunity 6
- Prevalence of Specific Anxiety Disorders 6
- Generalized Anxiety Disorder (GAD) 6
- Obsessive-Compulsive Disorder (OCD) 6
- Specific Phobias 7
- Social Phobias 7
- Panic Disorder 7
- Post Traumatic Stress Disorder (PTSD) 7
- Social Anxiety Disorder (SAD) 7
- Anxiety Disorders Can Strike At Any Age 7
- Table 1: Average Age of Onset for Select Anxiety Disorders (includes corresponding Graph/Chart) 8
- Women - The Most Affected Lot with Anxiety 8
- Table 2: Female to Male Ratio for Incidence of Anxiety Disorders by Type of Disorder (includes corresponding Graph/Chart) 8
Patent Expiries - A Major Impediment to Market Growth 9
- Patent Expiries of Select Leading Drugs Indicated for Anxiety Disorders 9
- Leading Drugs and Indications for Anxiety Disorders 9

3. PHARMACOLOGICAL TREATMENT FOR ANXIETY DISORDERS 11

Pharmacological Treatment 11
Available Treatment for Anxiety Disorders - In a Nutshell 12
Antidepressants for Anxiety Disorders 12
- Selective Serotonin Reuptake Inhibitors (SSRIs) 12
- Zoloft (Sertraline) 13
- Paxil (Paroxetine) 13
- Prozac (Fluoxetine) 13
- Cipralex/Lexapro (Escitalopram) 13
- Competitive Scenario - Cymbalta Emerges as a Market Leader in Anti-Depressants Market 13
- Table 3: Select Leading Anti-Depressants indicated for Anxiety Disorders (2007-2009): Annual Revenues for Cymbalta, Lexapro, Paxil & Wellbutrin, Effexor, Zoloft, and Remeron in US$ Million (includes corresponding Graph/Chart) 15
- Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) 15
- Cymbalta (Duloxetine) 15
- Effexor (Venlafaxine) 15
- Monoamine Oxidase Inhibitors (MAOIs) 16
- Tricyclic and Tetracyclic Antidepressants (TCAs) 16
- Other Antidepressants 16
Sedatives 17
- Benzodiazepines (BZDs) 17
Other Medications 17
Obsessive Compulsive Disorder (OCD) Treatment 17
- Table 4: Dosing of Select Serotonin Reuptake Inhibitors in OCD Treatment 18
Generalized Anxiety Disorder (GAD) Treatment 18
- Drugs Indicated for the Treatment of Generalized Anxiety Disorder (GAD) 19
- Novel Therapies for GAD on the Anvil 20
- Novel Compounds Under Investigation for Generalized Anxiety Disorder (GAD) 20

4. DRUG PIPELINE ANALYSIS 21

Select Anti-Anxiety Pipeline Drugs in Phase III Development Stage and Filed for Approval 21
Select Anti-Anxiety Pipeline Drugs in Phase II Development Stage 21
Select Anti-Anxiety Pipeline Drugs in Phase I Development Stage 22

5. NON-PHARMACOLOGICAL TREATMENT 23

Psychological Treatment 23
- Cognitive Behavioral Therapy 23
- Relaxation Techniques 23
- Biofeedback 23
- Hypnotherapy 23
- Meditation 23
- Natural Remedies for Treating Anxiety 24
Acupuncture 24
Other Treatment Options 24
- Support Program 24
- Changes in Lifestyle 24

6. ANXIETY DISORDERS - THE DISEASE, CAUSES, SYMPTOMS, AND EVALUATION METHODS 25

What is Anxiety Disorder? 25
Types of Anxiety Disorders 25
A Review of Anxiety Disorders 25
- Generalized Anxiety Disorder (GAD) 25
- Panic Disorder 26
- Phobias 26
- Agoraphobia 27
- Social Phobia 27
- Obsessive-Compulsive Disorder (OCD) 28
- Symptoms, Obsessions, and Compulsions of Obsessive- Compulsive Disorder 29
- Particular Phobic Anxiety Disorder (PPAD) 29
- Post-Traumatic Stress Disorder (PTSD) 29
- Separation Anxiety Disorder (SAD) 30
Anxiety Disorders in Children 30
Anxiety Disorders in Teens 31
Causes and Factors for Anxiety Disorder 31
Symptoms 32
Diagnosis for Anxiety Disorders 33

7. PRODUCT APPROVALS AND LAUNCHES 34

Sun Pharma Receives FDA Approval to Commercialize Generic Cymbalta 34
Impax Receives Tentative FDA Approval for Generic Version of Cymbalta 34
Actavis Receives FDA Approval for Alprazolam 34
Sun Pharma Receives FDA Approval to Generic Version of Alprazolam 34
Bafna Pharmaceuticals Receives Approval for Anxiety Drug in UK 34
Coenzyme-A Technologies Introduces MODULATOR MATRIX I 35
Sun Pharma to Launch Generic Version of Venlafaxine 35
Eli Lilly Receives FDA Approval for Cymbalta for Treating GAD 35
Aurobindo Pharma Receives Tentative US FDA Approval for Escitalopram 35
Boehringer Ingelheim and Eli Lilly Obtain Approval for Cymbalta in Canada 36
Medtronic' s Reclaim Deep Brain Stimulation Therapy Receives CE-Mark Approval 36
Otsuka Pharmaceutical and BMS Obtain FDA Approval for sNDA 36
Servier Obtains EMEA Approval for Valdoxan in Treating Major Depressive Episodes 37
Boehringer Ingelheim and Eli Lilly Receive EU Approval for Cymbalta in GAD 37
AstraZeneca Files for Approval of Seroquel XR for GAD in Europe 37
Glenmark Pharmaceuticals Launches Hydroxyzine Hydrochloride Tablets 38
Jazz Pharma Launches Once-A-Day LUVOX(r) CR Extended-Release Capsules 38

8. RECENT INDUSTRY ACTIVITY 39

Euthymics Acquires DOV Pharma 39
Abbott Acquires Solvay Pharmaceuticals 39
Pfizer Withdraws sNDA for Lyrica in Treating GAD 39
Eli Lilly Drags Sun Pharma to Court for Alleged Infringment of Cymbalta Patent 40
Pfizer Discontinues Late Stage Development of GAD Drug Candidate 40
Pacgen Biopharmaceuticals Acquires Xphase Pharmaceuticals 40
GSK Inks Agreement for Divesting Wellbutrin XL(r) Rights to Biovail International 41
Ligand Pharmaceuticals Acquires Neurogen 41
FDA Seeks Additional Information for Seroquel XR sNDA in GAD Treatment 41
AstraZeneca' s Seroquel XR(tm) Shows Improvement in GAD Symptoms 41
Synosia Therapeutics Begins Phase II Efficacy Trial for Rufinamide 42
Ambien CR(r) Improves Chronic Insomnia in Patients with Co-morbid GAD 42
AstraZeneca Files sNDA for Seroquel XR for Treating GAD 42
Bionomics Concludes GMP Synthesis of BNC210 43
OJSC Pharmstandard to Take Over Afobazol(r) Trademark 43

9. FOCUS ON SELECT MAJOR PLAYERS 44

AstraZeneca Plc. (UK) 44
Boehringer Ingelheim GmbH (Germany) 44
Bristol-Myers Squibb Company (US) 44
Eli Lilly and Company (US) 45
F. Hoffmann-La Roche Ltd. (Switzerland) 45
Forest Laboratories, Inc. (US) 46
GlaxoSmithKline Plc. (UK) 46
H. Lundbeck A/S (Denmark) 47
Mylan, Inc. (US) 47
Neurocrine Biosciences, Inc. (US) 48
Pfizer, Inc. (US) 48
Ratiopharm (Germany) 48
Sanofi-Aventis (France) 48
Valeant Pharmaceuticals International (US) 49
Watson Laboratories, Inc. (US) 49

10. GLOBAL MARKET PERSPECTIVE 50

Table 5: World Recent Past, Current and Future Analysis for Anxiety Disorders by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 50
Table 6: World Historic Review for Anxiety Disorders by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 51
Table 7: World 15-Year Perspective for Anxiety Disorders by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2003, 2010 and 2017 (includes corresponding Graph/Chart) 52

11. THE UNITED STATES 53

A. Market Analysis 53
- Current and Future Analysis 53
- Anxiety Disorders - A Major Health Burden 53
- Prevalence of Anxiety Disorders 53
- Table 8: US Prevalence of Anxiety Disorders by Type (includes corresponding Graph/Chart) 54
- Product Approvals and Launches 54
- Strategic Corporate Developments 57
- Select Players 60
- Bristol-Myers Squibb Company 60
- Eli Lilly and Company 60
- Forest Laboratories, Inc. 61
- Mylan, Inc. 61
- Neurocrine Biosciences, Inc. 61
- Pfizer, Inc. 62
- Valeant Pharmaceuticals International 62
- Watson Laboratories, Inc. 62
B. Market Analytics 63
- Table 9: US Recent Past, Current & Future Analysis for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 63
- Table 10: US Historic Review for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 63

12. EUROPE 64

A. Market Analysis 64
- Current & Future Analysis 64
- Product Launches/Approvals 64
B. Market Analytics 65
- Table 11: European Recent Past, Current & Future Analysis for Anxiety Disorders by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 65
- Table 12: European Historic Review for Anxiety Disorders Market by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 66
- Table 13: European 15-Year Perspective for Anxiety Disorders by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 67

12a. FRANCE 68

A. Market Analysis 68
- Current & Future Analysis 68
- Clinical Trials/Product Approvals 68
- Select Player 69
- Sanofi-Aventis 69
B. Market Analytics 69
- Table 14: French Recent Past, Current & Future Analysis for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 69
- Table 15: French Historic Review for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 70

12b. GERMANY 71

A. Market Analysis 71
- Current & Future Analysis 71
- Product Approval 71
- Select Players 71
- Boehringer Ingelheim GmbH 71
- Ratiopharm 72
B. Market Analytics 72
- Table 16: German Recent Past, Current & Future Analysis for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 72
- Table 17: German Historic Review for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 73

12c. ITALY 74

A. Market Analysis 74
- Current & Future Analysis 74
- Select Regional Player 74
- Polifarma SpA 74
B. Market Analytics 74
- Table 18: Italian Recent Past, Current & Future Analysis for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 74
- Table 19: Italian Historic Review for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 75

12d. THE UNITED KINGDOM 76

A. Market Analysis 76
- Current & Future Analysis 76
- An Overview of the Market Opportunity 76
- Table 20: Prevalence of Depression and Anxiety Disorders in the UK (2006): Percentage of Adult Population (16-75 Years) Affection by Condition (includes corresponding Graph/Chart) 76
- Product Approvals/Clinical Trials 77
- Select Players 78
- AstraZeneca Plc. 78
- GlaxoSmithKline Plc. 78
B. Market Analytics 79
- Table 21: UK Recent Past, Current & Future Analysis for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 79
- Table 22: UK Historic Review for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 79

12e. SPAIN 80

Market Analysis 80
- Table 23: Spanish Recent Past, Current & Future Analysis for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 80
- Table 24: Spanish Historic Review for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 80

2f. REST OF EUROPE 81

A. Market Analysis 81
- Current & Future Analysis 81
- Strategic Corporate Developments 81
- Select Players 81
- F. Hoffmann-La Roche Ltd. (Switzerland) 81
- H. Lundbeck A/S (Denmark) 82
- UCB SA (Belgium) 82
B. Market Analytics 83
- Table 25: Rest of Europe Recent Past, Current & Future Analysis for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 83
- Table 26: Rest of Europe Historic Review for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 83

13. ASIA-PACIFIC 84

A. Market Analysis 84
- Current & Future Analysis 84
- Anxiety and Depression - A Major Debilitating Condition in Australia 84
- Table 27: 12-Month Prevalence of Anxiety Disorders in Australia by Age Group (2006) (includes corresponding Graph/Chart) 84
- Strategic Corporate Development 85
- Key Player 85
- Ranbaxy Laboratories Limited (India) 85
B. Market Analytics 86
- Table 28: Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 86
- Table 29: Asia-Pacific Historic Review for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 86

14. REST OF WORLD 87

A. Market Analysis 87
- Current & Future Analysis 87
- Product Approval 87
- Select Player 87
- Ranbaxy Egypt Ltd. (Egypt) 87
B. Market Analytics 88
- Table 30: Rest of World Recent Past, Current & Future Analysis for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 88
- Table 31: Rest of World Historic Review for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 89

使用指南產品及服務須知網站導覽

星期一到星期五 / 9:30am - 6:00pm
TEL: 02-2729-4219 (+886-2-2729-4219)
E-mail: tw-info@gii.co.jp

全球焦慮症市場

Anxiety Disorders

簡介

目錄

第1章 介紹，方法論，產品定義

第2章 業界概要

第3章 焦慮症的藥理學的治療

第4章 藥開發平台分析

第5章 非藥理學的治療

第6章 焦慮症:疾病，原因，症狀，評估方法

第7章 產品核可與上市

第8章 最近的業界活動

第9章 主要加入企業

第10章 全球市場展望

第11章 美國

第12章 歐洲

第13章 亞太地區

第14章 其他各國

競爭簡介:63公司

目錄

Abstract

Table of Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

2. INDUSTRY OVERVIEW 5

3. PHARMACOLOGICAL TREATMENT FOR ANXIETY DISORDERS 11

4. DRUG PIPELINE ANALYSIS 21

5. NON-PHARMACOLOGICAL TREATMENT 23

6. ANXIETY DISORDERS - THE DISEASE, CAUSES, SYMPTOMS, AND EVALUATION METHODS 25

7. PRODUCT APPROVALS AND LAUNCHES 34

8. RECENT INDUSTRY ACTIVITY 39

9. FOCUS ON SELECT MAJOR PLAYERS 44

10. GLOBAL MARKET PERSPECTIVE 50

11. THE UNITED STATES 53

12. EUROPE 64

12a. FRANCE 68

12b. GERMANY 71

12c. ITALY 74

12d. THE UNITED KINGDOM 76

12e. SPAIN 80

2f. REST OF EUROPE 81

13. ASIA-PACIFIC 84

14. REST OF WORLD 87

COMPETITIVE LANDSCAPE

相關商品

精神病相關市場調查報告書

Global Industry Analysts, Inc.發行的製藥相關市場調查報告書

Email Alert(Email 通知) - 最新市場調查報告書

第1章介紹，方法論，產品定義

第2章業界概要

第3章焦慮症的藥理學的治療

第4章藥開發平台分析

第5章非藥理學的治療

第6章焦慮症:疾病，原因，症狀，評估方法

第7章產品核可與上市

第8章最近的業界活動

第9章主要加入企業

第10章全球市場展望

第11章美國

第12章歐洲

第13章亞太地區

第14章其他各國